Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Scilex Holding Co

SCLX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Pharmaceuticals ·

USA Micro Cap Analyst: N/A

Last Close

$5.73

▼ -1.21%

Market Cap $48.66M · Vol 7.56K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$48.66M

Micro Cap

Div Yield

N/A

Dividend with no set frequency

EPS Growth

N/A

YoY

RSI (14)

33.73

Momentum

Beta

1.64

vs Market

52W High

$21.28

73.07% below

52W Low

$2.62

119.11% above

Volume

7.56K

Avg 13.59K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

88.34%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Scilex Holding Co (SCLX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does SCLX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-15.24%

-26.91%

+55.45%

+13.33%

YTD

-24.57%

-46.31%

-91.65%

-97.36%

Financials & Valuation

TTM · Annual

Total Revenue	$30.25M
Net Income	$-374,053,000.00
Revenue Growth (YoY)	-22.78%
Gross Margin	50.54%
Operating Margin	-900.09%
Net Profit Margin	-1,236.42%
ROE	N/A
ROA · ROIC	-163.35% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	2.77
P/B	N/A
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	8.49M

Technical Indicators

50-Day SMA	$7.20
200-Day SMA	$6.82
RSI (14)	33.73
Beta	1.64
52-Week High	$21.28
52-Week Low	$2.62

Volume Today	7.56K
Avg Daily Volume (30D)	13.59K
Relative Volume	0.56x
Volatility (10D)	63.78
Volatility (30D)	72.10
Free Float	88.34%

Analyst Consensus

N/A

Current Price $5.73

Mean Target N/A

52W Low$2.62 52W High$21.28

Current

Target

$2.62 $21.28

Current Analyst target

· 0 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00YJTT5F2

ISINUS80880W2052

CountryUnited States of America

Sub-IndustryProprietary & Advanced Pharmaceuticals

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

MRK Merck & Co Inc +2.39% MRK.DE Merck KGaA -0.07% HALO Halozyme Therapeutics Inc +1.93% 4151.T Kyowa Kirin Co Ltd -1.85% 000100.KS Yuhan Corp -1.32%

Company Profile

Scilex Holding Company is focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company’s commercial products include ZTlidoO (lidocaine topical system) 1.8% for the relief of neuropathic pain associated with postherpetic neuralgia (PHN); ELYXYB, a ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and GLOPERBA, the liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, it focuses on product candidates, including SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXAO), an epidural injections formulation to treat lumbosacral radicular pain, or sciatica; SP-103 (lidocaine topical system) 5.4%, a ZTlido formulation, for the treatment of acute pain; and SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (SP-104) for fibromyalgia treatment.